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1. Introduction 
Protein-protein interactions form the basis of many cellular processes. Disruption or 
deregulation of these complex interactions is the main cause of a significant number of 
human ailments. Consequently, there is intense research effort to design inhibitors that 
target specific protein-protein interactions. This places intricate protein-protein interactions 
in the heart of the development for novel drug leads. The emergence of ‘omic’ technologies, 
namely genomics, transcriptomics and proteomics, has greatly accelerated our 
understanding of the protein-protein interaction networks leading to the discovery of a 
number of proteins and their interaction interface as potential drug targets.  
The “druggable proteins” are targeted by commercially viable, and preferably orally 
bioavailable, therapeutics [1]. These drugs are usually small organic molecules that 
function as competitive or noncompetitive proteins inhibitors [2]. On the other hand, 
many “undruggable” proteins are important targets in various disease states. These 
proteins are considered undruggable because they lack a cavity for the small organic 
inhibitors to bind and they interact with their protein partners through extensive and flat 
surfaces. The use of protein based therapeutics expands the repertoire of “druggable 
proteins” by targeting those proteins that cannot be inhibited by the available small 
molecules [3]. Besides their improved specificity offered by their high compatibility with 
the target proteins, the major advantage of peptide therapeutics is their reduced 
immunogenicity and improved safety. On the other hand, low oral bioavailability, low 
protease/peptidase resistance, low cellular uptake, high rate of hepatic and renal 
clearance, high biodegradability and high flexibility are some limitations of peptides as 
therapeutics [4].  
Peptide drugs take advantage of the highly specific and selective interaction between 
proteins. The peptide is usually based on the sequence of the binding region between the 
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two proteins. The linear sequences might originate from a loop within a structured domain, 
or from a disordered region in protein termini or between defined domains. In order to 
achieve desired efficacy, following delivery to the correct cellular compartment, the 
designed peptide needs to target the appropriate site and bind it. A perfect therapeutic 
agent is then a short protein sequence that will reach, bind and modulate the function of a 
target protein for the required amount of time and efficacy. These linear sequences are 
difficult to discover due to their short length and a tendency to reside in disordered regions 
in proteins. Increase in the available structural information on the protein – protein 
interactions has spurred the design of novel peptide therapeuticals. Furthermore, it is now 
possible to screen and select high affinity peptides for these targets with the advent of 
peptide libraries and array techniques. 
Peptide drugs may function by interacting with different targets such as proteins, lipids, 
nucleotides or metabolites. Particularly, there is significant research focused on 
antimicrobial peptides that target lipid cell membranes. This review focuses on the 
challenges and opportunities in the design and development of peptide based drugs that 
bind and inhibit some important protein targets. 
2. Protein–peptide interactions 
Diverse cellular events such as protein and vesicle trafficking, gene expression, DNA repair, 
control of the cytoskeleton and targeted protein degradation as well as signaling cascades 
are regulated through dynamic protein interactions [5-7]. Enhancing the efficacy of a 
peptide therapeutic addressing one of these processes is tightly bound to basic principles 
governing protein-peptide interactions. Despite their significance and estimated abundance, 
a large fraction of protein-peptide interactions lack detailed characterization and some 
questions of scientific and commercial interest remain: How does a peptide overcome the 
energetic cost involved in switching from an unstructured, flexible peptide to a rigid, well-
defined bound structure? What is the recognition process for the binding event? What 
stabilizes these interactions? If a peptide binds to a protein, what is the spatial configuration 
and what is the strength of this interaction? If they don’t bind each other, can they be made 
to bind by modifications? The increasing number of resolved protein-peptide structures 
sheds light into the mechanistic details of binding.  
2.1. Protein – Peptide structures in the PDB  
The rational design of peptide drugs is stimulated by the availability of structural 
information on protein – protein complexes. Peptides derived from the binding region of an 
inhibitor protein usually serve as a starting point in the design of peptide inhibitors against 
the protein – protein interaction. Coordinate and distance information about the binding 
interface can be based on X-ray crystallography or NMR methods. Other experimental 
methods that identify interface residues include alanine scanning mutagenesis [8], chemical 
modification, mass spectrometry and phage display [9]. 
 
Protein-Peptide Interactions Revolutionize Drug Development 51 
We have filtered the Protein Data Bank [10] for the keyword “peptide” in the structure 
description and with chain length between 5 to 35 amino acids and found a total of 1816 
crystal structures and 307 structures determined by solution NMR in March 2012. 
Additionally, two electron microscopy structures of the Escherichia coli 70S ribosome in the 
presence of the leader peptide were also reported. A 2010 study clustered the complex 
structures determined by crystallography in the Pep-X database (http://pepx.switchlab.org) 
[11]. This database contains 505 nonredundant protein-peptide interface complexes. 14% of 
these complexes are with the Major Histocompatibility Complex, 12% of them are with 
thrombin and 8% are with alpha-ligand binding domain. Another nonredundant protein – 
peptide database of 103 structures was reported in 2010 by the Schueler-Furman group [12].  
The peptide binding site is usually a large and shallow pocket on the protein surface and it 
does not change its conformation upon peptide binding. In addition, hydrogen bonds with 
the peptide backbone and interactions with hot spot residues provide the enthalpic 
contribution to protein – peptide recognition. The protein – peptide interface is enriched in 
Leu and Ile as well as aromatic residues. The protein – peptide interface was shown to 
resemble the core of the protein, with more hydrophobic residues than the protein surface 
and with the structural motifs found in protein folds [12, 13].  
2.2. Protein interaction domains in peptide recognition 
It has become apparent that a significant number of protein interactions are commonly 
formed between conserved protein recognition domains and short linear peptide motifs, 
often less than 10 amino acids in length [14-17]. Members of a given protein domain family 
usually recognize a consensus motif but they may recognize different variations of this motif 
and they may possess unique binding specificities [17-24].  
Peptides can interact with globular protein domains in very diverse ways. These include 
binding of a peptide onto a protein domain by forming an additional beta-sheet, binding to 
clefts in extended beta or proline type II helical conformations or adoption of a helical 
conformation. For example, SH2 and phosphotyrosine-binding (PTB) domains recognize 
phosphotyrosine motifs [6, 25-27], while polyProline helices are recognized by SH3, WW 
and EVH1 domains [14, 28, 29] (Figure 1). 14-3-3 proteins, FHA and WD40 domains 
recognize phosphothreonine/serine-containing elements [30]; bromo and chromo domains 
recognize acetylated or methylated lysine [31, 32]; VHL proteins recognize hydroxyproline 
motifs [33]. On the other hand, short amino acid motifs at the carboxyl termini of target 
proteins, such as ion channels, are important for recognition by PDZ domains [34].  
Design of peptide based inhibitors against proteins with such modules is hampered by the 
similarity between the recognized peptide sequences. However the structural information 
available clarifies many ambiguities regarding protein-peptide interactions. The specificity 
and selectivity of the protein modules in the cell suggest the presence of a mechanism 
whereby a selective peptide drug can be designed that interferes with the binding of protein 
domains to their respective partners. 
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Figure 1. SH3 domain (gray) in complex with a polyproline peptide (PDB code: 1n5z), SH2 domain 
(gray) in complex with a phosphotyrosine peptide (PDB code: 1sps) 
3. Identification/development of peptide ligand drugs 
Figure 2 illustrates the primary steps involved in the design and development of peptide 
ligand drugs. The initial step in peptide drug design is the identification of the protein 
target. This is usually a protein that is implicated in a disease state. If possible (and/or 
available), the interaction partners of the target protein are also determined. Information 
from structure-activity relationship studies is then used for rational design. Structural 
information of the protein – protein interface is fundamental for rational drug design. If 
there is no information about the interacting partner, combinatorial approaches, such as 
phage display, peptide arrays or peptide aptamers, should be used to screen tight binding 
peptide sequences. Rational design may follow combinatorial approaches to design a 
peptide sequence with improved specificity and higher affinity. Once a tight binding 
potential peptide sequence is identified, the peptide is usually modified to enhance stability, 
uptake and delivery. These may include alteration of amino acids to nonnatural amino 
acids, cyclization of the peptide or constraining the peptide so that it forms an alpha helix. 
This modified peptide is a peptidomimetic, which has the properties of the peptide with 
respect to binding mechanism but also has higher stability and uptake potential than a 
natural peptide ligand. After in vitro tests of the modified peptide, in vivo tests and clinical 
trials are performed. Peptide may undergo further modifications during these tests. The 
ones that pass clinical trials are then marketed. 
3.1. Rational design 
Increase in the availability of crystallographic structures of protein complexes has conveyed 
valuable information for rational drug design efforts [36, 37]. Given a known (or predicted) 
protein – protein complex structure, inhibitors that target the interface between the two 
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proteins can interfere with this interaction. Design of peptides based on the interface has 
also been an area of intense research [38, 39].  
 
Figure 2. Schematic diagram of drug design (Target protein is beta-lactamase (PDB code: 1zg4, [35]) , 
photo of the patient in hospital by Randy Glasbergen (www.glasbergen.com, Copyright 2002). 
Docking of small organic molecules to protein targets has shown good progress with the 
advent of docking, virtual screening and pharmacophore building algorithms [40]. 
However, the prediction of the complex structure between a peptide ligand and its protein 
partner is not easy due to the flexible nature of peptides. The solution structure and the 
bound structure of peptides are usually different, with the peptide adopting its bound 
conformation only in the presence of the protein [41]. In addition, protein – peptide docking 
studies are further complicated by the absence of a cavity for peptide binding, because 
protein – peptide interaction sites are usually shallow pockets on the surface [12]. Several 
algorithms have been proposed for protein – flexible peptide docking. Three recent 
algorithms are the molecular dynamics based Dynadock [42], the Monte Carlo based 
FlexPepDock [43] and PepCrawler, which uses the protein – protein interaction interface 
structure and the Rapidly-exploring Random Trees approach [39].  
With the advent of high-throughput technologies, rational drug design led to the 
development of combinatorial chemistry to provide diverse libraries and arrays for drug 
discovery [44]. Combined with the screening of libraries and arrays against target proteins, 
protein target 
rational 
clinical trials 
in vivo peptide 
evaluation  
MARKET 
combinatorial approches 
phage display 
peptide array 
peptide 
improvement 
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rational drug design is a powerful tool for discovering novel pharmacologically active small 
peptide leads. These drug leads can further be engineered for the development of future 
generations of novel therapeuticals.  
3.2. Peptide phage display 
There are a number of display technologies (phage, ribosome, mRNA, bacterial, etc.) to 
select peptides for defined proteins targets. In this review, the discussion of display 
technologies will be restricted to phage display, the most widely utilized display method. 
Phage display technique is based on displaying peptides on the surface of a bacteriophage 
by expressing the peptides as fusions to capsid proteins [45]. Using either lytic or 
filamentous phage or phagemid vectors, various phage-displayed libraries have been 
designed but the most common systems are based on filamentous phages in which peptides 
are fused to coat proteins. The choice of the coat protein is an important factor in 
modulating the display valency of the fusion protein on the phage particle which can vary 
between less than one and several thousand copies per virion on average [44]. The fact that a 
large number of virions occupy a small volume makes it possible to express billions of 
peptides on phage particles for constructing libraries of the required diversity. In such 
libraries, each phage displays a unique random peptide. In cases where the peptides are 
critically big to disrupt the integrity of the capsid at high copies, they can be constrained by 
cyclization through incorporating pairs of cysteine residues forming intramolecular 
disulfide bonds [44, 45]. Affinity purification is often used to screen phage displaying 
peptides of interest. Several rounds of screening might be necessary in order to isolate target 
specific binders. Finally, the tight binding peptides are identified by rapid sequence analysis 
[37, 45]. Unlike rational design, screening phage displayed libraries for bioactive ligands 
requires no prior knowledge of the target structure [44].  
Mirror image phage display is an elegant approach to obtain peptide ligands in the D-
conformation which are resistant to gut and serum proteases. In principle, the selection is 
carried out against a target protein synthesized in the D-amino acid configuration (the 
mirror image of the original target) using a phage library of peptides in the naturally 
occurring L-conformation. For reasons of symmetry, the mirror images of these phage-
displayed peptides interact with the target protein of the natural handedness [46]. 
3.3. Peptide arrays 
Systematically arranged peptides on a solid support, peptide arrays, show great promise in 
screening lead drugs [47]. Peptide arrays synthesized on cellulose membranes are very 
versatile and their preparation is very rapid and cost-effective [48]. Peptide arrays are 
primarily classilified based on the method used for assembly of peptides on the surface of 
the solid support. The in situ peptide array has peptides directly synthesized on the solid 
surface. In contrast, spotting peptide array relies on immobilization of presynthesized 
peptides onto a suitably derivatized solid surface [47, 49].  
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The two techniques used in situ peptide synthesis are the photolithographic synthesis (light-
directed parallel chemical synthesis) and the SPOT synthesis. The former approach, first 
reported by Fodor et al [50], uses photolabile protecting groups to simultaneously 
synthesize thousands of spots, each with a unique peptide sequence. Improvements to this 
work have been reported by McGall et al [51], Pellois et al [52] and Li et al [53, 54]. In the 
SPOT technique, first reported by Frank [55, 56], peptides are synthesized by sequential 
spotting of small volumes of activated amino acids to a porous membrane. Advances have 
made rapid synthesis of a large number of peptides possible [57]. The advantage of in situ 
technique is that it avoids conventional synthesis of each peptide sequence found on the 
array. 
The spotting array technique is preferable when small numbers of peptides are needed in 
the array or when the peptides will be used to prepare large numbers of identical arrays. 
There are currently a variety of methods for slide derivatization and immobilization of 
peptides to the surface [49]. In any application, chemical surfaces should allow efficient 
immobilization using the appropriately chosen functional groups present in a peptide. 
Additionally, the protocol to introduce the functional group, the tag, to the peptide should 
not be tedious.  
3.4. Peptide aptamers 
Peptide aptamers are most commonly used as disrupters of protein–protein interactions in 
vivo. They are combinatorial protein molecules (Figure 3), which consist of a variable 
peptide loop attached at both ends to an inert, constant scaffold protein [58-60]. The scaffold 
should preferable be small, composed of a single chain, and with a highly stable structure 
[61]. The choice between different scaffolds such as thioredoxin A (TrxA) [62], 
staphylococcus nuclease [63], human stefin A [64], and green fluorescent protein [65] is 
made by taking into account the intended use of the peptide [59]. Scaffold structures restrict 
the conformation of the peptide such that the loop can only adopt a discrete shape from the 
conformational space available to it. The variable loop of the aptamer, as constrained on 
both ends, offers greater specificity and higher affinity for their target surfaces as compared 
to the free peptide [66]. The higher affinity is a result of lower entropic cost due to binding 
of a constrained peptide compared with the entropic cost of constraining the peptide upon 
binding. 
 
Figure 3. Peptide aptamer, a) unfolded form, b) folded form. Black region shows the scaffold protein 
and red loop shows the variable peptide. 
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Once the scaffold has been chosen, the three basic principles followed in aptamer design are 
(i) generation of a pool of peptides commonly using combinatorial approaches, (ii) selection 
to find best candidates, and (iii) amplification by expression in bacterial cells, such as 
Escherichia coli [59].  
4. Toward a peptide drug with better bioavailability and stability 
Peptides are gaining increasing attention as drug leads over small molecule drugs featured 
by their high affinity and specificity to interact with their targets together with their low 
toxicity profiles [67]. Unfortunately, the major limitations encountered in stability and 
delivery, overshadow their remarkable success. To be competitive and profitable, the lead 
peptide, which is usually designed based on the protein – protein interface, needs to be 
improved for better cell membrane permeability and stability and ADME (Absorption, 
Distribution, Metabolism, Excretion) properties [4, 68, 69]. Initial attempts were mainly 
focused on the improvement of existing peptide leads but the need for peptides with better 
physicochemical properties and pharmacokinetic profiles eventually has given rise to the 
field of peptidomimetics, the development of small peptide like compounds with the ability 
to mimic the structure or action of the raw peptide. The engineering of the desired property 
carries the new small molecule beyond the capabilities of the raw peptide lead [70]. 
4.1. Improvement of half life and stability  
Peptides can display half lives as short as a few minutes, which is usually too short deliver 
sufficient drug amounts to target tissues. Consequently, many peptide drugs with exciting 
pharmacological activities prove to be ineffective in vivo. The short half life, which renders 
the peptide ineffective, is primarily due to its fast renal clearance, connected to its hydrophilic 
property and small size, and its poor metabolic stability and biodegradability as a result of 
enzymatic degradation by proteolytic enzymes (proteases and peptidases) of the blood, 
liver, and kidney. Hence different strategies for targeted modifications of peptide drugs in 
order to prolong their plasma half lives are highly demanded to improve drugs’ 
pharmacokinetic profiles. [67, 71].  
In performing a modification to a peptide drug to protect it from proteolytic cleavage, each 
peptide drug should be considered as a separate entity since, based on the sequence, each is 
a target for a different group of enzymes. This makes the detailed knowledge of proteases, 
their tissue localization and cleavage specificity very essential [71]. Only then can 
modifications on a particular drug be imposed to improve its susceptibility towards 
proteolytic enzymes targeting it. Protease resistance can be conferred by substituting the 
natural amino acids by unnatural amino acids (D-), an N-methyl-alpha-amino acid, or a 
beta-amino acid. The amide bond between two amino acids may be replaced. The N- or C-
termini may be blocked or carbohydrate chains can be added. N-terminus may be esterified 
or pegylated. In addition, controlled release parenteral delivery, mucosal delivery and 
transdermal delivery have emerged as alternative strategies to oral delivery which exposes 
the peptide to stomach acid [4]. 
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Constraining a peptide from an unstructured ensemble of many configurations to a fixed 
conformation serves two purposes; the conformational heterogeneity of the peptide in the 
unbound form is reduced, hence reducing the entropic cost associated with binding and more 
importantly the protease resistance of the peptide is enhanced [72]. Some example strategies 
of constraining the peptide are to “staple” or crosslink the peptide to assume an alpha helical 
shape [72] (Figure 4A), to cyclize the beta hairpin form [73] (Figure 4B), or to change the 
backbone such that it is nonrotatable [74]. Another similar modification mimics the structure 
of plant derived cyclotides, which contain a cyclic cysteine knot [75] (Figure 4C).  
 
Figure 4. Examples of constrained peptides A) Cyclotide with three disulfide bridges shown in gold 
[76] 2k7g B) Cyclic beta-hairpin 2ns4 [77] C) Stapled peptide with the so-called staple, or hydrocarbon 
link shown in gold [78] 2yja 
In many cases, modification of the peptide drug significantly increases enzymatic stability, 
but activity loss is always an issue. Therefore it is important that improved stability 
counterbalances activity loss. For this reason, co-administration of peptides with inhibitors 
of enzymes that target the peptide might be offered as an attractive alternative tool to 
chemical modifications to increase peptide stability [79-81]. 
4.2. Enhancing uptake and delivery 
An important challenge in the design and development of peptide based drugs is their size 
and hydrophilic character, preventing their spontaneous uptake by the cell. For peptides 
which target membrane receptors, delivery to the target sites may be made possible with the 
application of liposomes or nano- and microparticles. On the other hand, in case of peptide 
drugs that target intracellular proteins, intracellular delivery through the biological 
membrane is crucial for their efficacy. Since poor uptake and limited delivery has been an 
important drawback hampering the acceptance of peptide drugs in the pharmaceutical 
market, different approaches have been proposed to address this problem. 
Sustained delivery systems based on biodegradable polymers from renewable resourses 
such as chitosan and its derivatives, from petroleum resources such as PLGA (poly-lactic-co-
glycolic acid) or PGA (polyglycolide) or blends of these have been receiving increasing 
attention following the nanotechnological advances applicable to peptide delivery [82-84]. 
As an example, progress made in the use of chitosan in peptide delivery is detailed below. 
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The polysaccharide based chitosan is a nontoxic linear polymer composed of -1,4 linked 
D-glucosamine derived from the deacetylation of the naturally occurring polymer chitin. 
The biodegradable, biocompatible, bioadhesive, and permeation enhancing properties have 
made chitosan and its derivatives, such as N-trimethyl chitosan, outstanding polymers for 
delivery [85]. In addition to nasal, pulmonary, transdermal, and parenteral delivery routes 
using chitosan-based nano- and microparticle carriers, chitosan coated particles or 
pegylated chitosan particles receive particular interest for the delivery of peptides [83, 86]. 
Use of chitosan-based nano- and microparticles for peptide antigens based on luteinizing 
hormone-releasing hormone [87], peptide hormone insulin [88], glutathione [89, 90], 
heparin [91], and calcitonin [92] are just a few examples on the application of chitosan in 
peptide delivery. 
Liposomes, regarded as drug delivery vehicles, are also widely used as carriers of peptides. 
They also enhance the local availability of peptides, protecting them from proteolytic 
action. Liposomes are artificially prepared microscopic vesicles composed of a lipid 
bilayer. The therapeutic peptide is encapsulated inside the aqueous compartment 
surrounded by the lipid membrane. Various types of liposome formulations have been 
prepared with different dimensions, composition, surface charge and structure to induce 
specificity and cell targeting [93, 94]. Different liposome formulations were tested for the 
administration of peptides such as insulin [95], calcitonin [96] and vasoactive intestinal 
peptide (VIP) [97]. 
There is significant discussion regarding the use of cell-penetrating peptides (CPPs) as tools 
to carry peptides to desired targets [37]. CPPs are usually 10-30 amino acids long and harbor 
a hydrophobic and a basic region. The major advantage of CPPs over antimicrobial 
peptides, which simply target the lipid membrane, is that CPPs help carry cargo into the cell 
in an energy independent manner without disrupting the cell membrane, hence can target 
intracellular enzymes and machinery [98, 99]. Two CPPs that have been studied in detail are 
the TAT peptide (GRKKRRQRRRPPQ) [100, 101] and penetratin (RQIKIWFQNRRMKWKK) 
[102, 103] . The mechanism of uptake has been proposed to be by endosomes at low 
concentrations [98]. Transient pore formation, and resulting direct penetration, was also 
proposed as a mechanism of uptake for Tat peptide at high concentrations [104]. In direct 
penetration, the membrane is transiently destabilized by the interaction of the basic residues 
(Arg) and the negatively charged components of the cell membrane. Another CPP, TP10 
(also known as transportan, AGYLLGKINLKALAALAKKIL), lacks arginine residues and 
has been suggested to be delivered by the endocytotic pathway or by the interaction of the 
positively charged Lysine residues with the membrane [105, 106]. Structure activity 
relationship studies on another CPP, pVEC (LLIILRRRIRKQAHAHSK) showed that 
mutation of arginines to alanine did not abolish uptake, but scrambling the sequence of the 
peptide or mutating the first five hydrophobic residues to alanine did [107]. Conjugation of 
peptide drugs to CPPs is particularly relevant in the treatment of diseases which require the 
relevant peptide to traverse the blood-brain barrier. 
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5. Therapeutical peptides, present and future 
5.1. Current status of peptide drugs 
Although the synthesis and clinical use of the first synthetic peptide, insulin, dates back to 
1920s [108, 109], it had not been possible to consider peptides as potential drugs before the 
introduction in 1960s by the 1984 Nobel Chemistry Prize Laureate Bruce Merrifield, of solid 
phase peptide synthesis, which lowered the production costs and time [110, 111]. Currently, 
the pharmaceutical industry and its contract manufacturers express their willingness to go 
into larger scale production using both solid- and solution-phase strategies. Today, there are 
more than 50 peptide drugs that have been approved for clinical use and the increasing 
number of peptides entering clinical trials now supports the notion that peptide drugs have 
a long and secure future. The targeted therapeutic areas of the present peptides include but 
are not limited to oncology, metabolic, cardiovascular and infectious diseases, all of which 
represent important markets. Table 1 includes a list of some of the peptide drugs that have 
reached high global sales (Pechon et al. development trends for peptide therapeutics, 
peptide therapeutics foundation, 2010 report).  
Currently, most of the peptide drugs are peptide hormones (such as insulin) or peptides that 
mimic hormones [4]. However, the number of peptide drugs that act as enzyme inhibitors 
[112] or as antimicrobial peptides [113] is increasing. 
5.2. Protein targets for potential peptide drugs 
New peptide drugs are currently under development for a variety of protein targets. Here 
we focus on three major disease states, namely HIV infection, cancer and Alzheimer’s 
disease and discuss some of the ongoing research toward the design and development of 
peptide drugs against these diseases. 
Primary HIV infection starts through recognition of its envolope glycoproteins (gp120 and 
gp41) by the CD4 receptors and CCR5 (macrophage) or CXCR4 (T cell) co-receptors on its 
target. Upon entry, the envelope protein undergoes a major conformational change and 
juxtaposes the viral and host membranes. Finally, the viral genome integrates into the 
host genome. The envelope proteins is the site of primary infection, therefore fusion 
inhibitor peptides blocking their interaction with the protein targets in the host might be 
regarded as potential drugs [121]. With this motive, initial efforts of the early 1990s have 
eventually lead to the development of the first approved anti HIV-agent originally 
designated DP-178, later T-20 now FUZEON or Enfuviritide, which is a synthetic peptide 
based on the C-terminal heptad repeat region (C-HR) sequence of HIV-1 gp41 (Table 1) 
[120]. Although it is highly effective in vitro, its limited use due to difficulties encountered 
in its administration has shown that this drug in this from is not the ultimate solution for 
HIV treatment. Continued research, supported with structural studies, has shown C34, 
also derived from the C-HR sequence of gp41, can compete with gp41 [122, 123]. T21 and 
N36, derived from the N-terminal heptad repeat region (N-HR) were also reported to be 
potent inhibitors [124, 125]. Based on the fact that peptides derived from C-HR and N-HR 
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regions of gp41 may serve as potent intibitors of HIV entry, intense research effort has 
been made for the rational design of different inhibitors based on these sequences. This 
also includes modifications such as incorporation of nonnatural and D-form amino acids 
(C34M3, [126]), synthesis of chimeric peptides (T1249, [123]) and even construction of 
fatty acid C-HR based conjugates (DP, [127]). For a detailed list, refer to the review by 
Naider and Anglister [121]. There is also continued research that focus on the sequences 
of CCR5 or CXCR4 receptors to design HIV-inhibitor peptides [128]. 
 
Peptide Brand name Target 
disease 
Target protein/ 
biological action 
Sequence Reference 
glatiramer 
acetate 
Copaxone, 
copolymer1 
Multiple 
sclerosis 
Unknown Random mixture 
of Glu, Ala, Lys, 
Tyr 
[114] 
leuprolide 
acetate  
lupron Prostate 
cancer, 
breast cancer
Binds 
gonadotropin-
releasing 
hormone receptor
Pyr-HWSY-D-
LLRP-NHEt  
[115] 
goserelin 
acetate 
Zoladex Prostate 
cancer, 
breast cancer
luteinising-
hormone 
releasing 
hormone analog 
 
p-EHWSY-D-
S(tBu)- 
LRP-AzaGly-
NH2, 
[116] 
octreotide 
acetate 
Sandostatin Acromegaly, 
carcinoid 
syndrome 
 H-D-F-c[CFD-
WKTC]-
tholacetate 
[117] 
exenatide  Byetta Type 2 
diabetes 
mellitus 
glucagon-like 
peptide 1 analog 
HGEGTFTSDLSK
QMEEEAVRLFIE
WLKNGGPSSGA
PPPS 
 
[118] 
teriparatide  Forteo osteoporosis  SVSEIQLMHNL
GKHLNSMERVE
WLRKKLQDVH
NF 
 
[119] 
enfuvirtide Fuzeon HIV Targets HIV-1 
fusion machinery
Ac-
YTSLIHSLIEESQ 
QQELNEQELLE
LD 
KWASLWNW F-
NH2 
[120] 
Table 1. Some peptide drugs that have reached high global sales  
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Despite current progress, there is continued challenge in developing anti-HIV peptides due 
to their rapid renal clearance, poor distribution, and susceptibility to peptidase degradation. 
Hence search for HIV fusion inhibitors has been extended to screening a wide range of 
different sources such as red algae Griffithsia. From the algal lectin Griffithsin, a small HIV-
1 entry inhibitor of 18-residues, Grifonin-1, was derived and this peptide was found to bind 
the HIV surface glycoprotein gp120 and block its binding with host surface receptors [129]. 
Envelope glycoproteins and cell surface receptors do not constitute the only target to 
prevent HIV infections. The cell-surface expressed nucleolin, which is one of the major RNA 
binding proteins of the nucleolus and serves as a binding protein for different ligands 
including HIV, might be another possible target in HIV treatment. The pentameric 
pseudopeptide HB-19 was found to inhibit HIV infection by binding to the nucleolin and to 
block the attachment of virus particles to cells. Hence HB-19 represents a potential anti-HIV 
drug [130, 131]. Since nucleoin at the cell surface is also a binding site for a variety of ligands 
implicated in tumorigenesis and angiogenesis, its potential as an anticancer drug has also 
been evaluated [131].  
Loss of apoptotic control has been implicated in many disease states ranging from cancer 
[132] to autoimmune diseases . Caspases, a group of proteases implicated in apoptosis and 
inflammatory response, are therefore an important drug target. The WEHD tetrapeptide 
was found to be an optimal peptide sequence for caspase inhibitors using positional 
scanning synthetic combinatorial library [133] and many variants of this sequence have been 
designed. These peptidomimetic lead compounds for caspase inhibition, such as 
Pralnacasan, VX-765, emricasan and NCX-1000, have been recently reviewed by MacKenzie 
et al. [134]. The structure of caspase-2 in complex with a pentapeptide [135] is shown in 
Figure 5.  
Estrogen receptors have been a drug target in breast and endometrial cancers since they 
regulate reproduction, maintain bone density and are important for central nervous system 
function. Peptide inhibitors that mimic and compete with the leucine-rich pentapeptide 
motif (LXXLL, where X is any residue) of the ER coactivator are promising lead compounds 
in the design of selective peptide inhibitors [136]. One modification to these lead 
compounds is using a hydrocarbon link to stabilize them in the alpha-helix form, also 
known as a stapled peptide [78]. The structure of the estrogen receptor in complex with a 
staple peptide is shown in Figure 5. 
Bcl-2 is another protein involved in apoptosis and it has been the target of many drug 
design efforts [3]. However, the shallow groove which interacts with its binding partners 
renders it “undruggable” and therefore peptide based drug design against Bcl-2 has 
emerged as a promising approach [137]. The structure of Bcl-xL in complex with a Bad 
peptide is shown in Figure 5.  
The phosphotyrosine recognition domain, SH2, is a subunit of many kinases, which are the 
key players in important signal transduction events. In Src kinases, SH2 – kinase domain 
intramolecular interaction keeps the kinase in its downregulated form [138], while in Stat3 
(signal transducer and activator of transcription 3), the SH2 domain serves as a binding site 
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for downstream signaling [68]. Loss of kinase regulation or constitutive kinase activation 
has been implicated in cancer and autoimmune diseases. As such, SH2 is an important drug 
target and SH2 inhibitor design is an area of intense research. The Stat3 SH2 recognition 
sequence pYXXQ (where pY is the phosphotyrosine and X is any residue) was modified into 
a lead peptidomimetic, nanomolar affinity was attained [68]. The structure of Grb2 SH2 
domain in complex with a pYXN-derivative [139] is shown in Figure 5.  
The proline rich AMAP-1 protein interacts with the SH3 domain of cortactin and this 
complex formation is implicated in tumor invasion [140]. This interface is therefore a drug 
target in breast cancer invasion and metastasis. The proline rich domain of AMAP-1 was 
used to design a proline rich peptide [141], which was then made cell-permeable by the 
addition of the HIV Tat sequence [142]. 
 
 
Figure 5. Some of the protein targets discussed in this review and their interaction with their designed 
peptide ligands. Caspase (PDB code: 3r6l), estrogen receptor (2yja), Bcl-2 (1g5j) and Grb2 SH2 domain 
(3ov1) are shown in silver surface representation and the peptide ligand is red.  
 
Protein-Peptide Interactions Revolutionize Drug Development 63 
The molecular origins of a number of neurodegenerative disorders such as Alzheimer’s, 
Huntington’s, Parkinson’s and Creutzfeldt-Jakob diseases have been associated with the 
aggregation of proteins [143, 144]. In particular, the pathological event in Alzheimer’s disease 
(AD) is the progressive accumulation of 42 residue -amyloid peptides and resulting 
formation of insoluble -amyloid fibrils [145]. Presently there is no cure for the treatment of 
AD but novel peptides that can inhibit and or reverse this abnormal conformational change 
are the subject of many recent reports. -amyloid fibrillogenesis involves the conversion of -
helix/random coil to -sheet motifs and proceeds via oligomeric and protofibrillar 
intermediates therefore it can be inhibited by destabilizing the -sheet-rich -amyloid 
intermediates, using -sheet breaker peptides [146-149]. One example of a -sheet breaker 
peptide, which comprises a short fragment of -amyloid peptide (KLVFF; residues 16-20), can 
bind full-length -amyloid peptide and prevent its assembly into amyloid fibrils [150]. The 
peptide LPFFD derived from another fragment of the -amyloid peptide (LVFFA; residues 
17-21) is another -sheet breaker that abolishes fibril formation [146, 147] . Permanne et al 
further modified this peptide to extend the serum half-life and increase the blood-brain 
barrier permeability [151] . Rationally designed hybrid molecules composed of β-breaker 
elements combined with aromatic moieties (e.g. D-Trp--aminoisobutyric acid) have also 
emerged as promising leads [152]. Development of beta-sheet breaker peptides have also 
been reported toward diabetes 2, which is another amyloidogenic disease state [153]. 
6. Conclusion 
As our understanding of complex biological networks increases, different proteins emerge as 
potential targets for peptide based drug development. Peptides are gaining increasing 
importance as drug leads over small molecule drugs featured by their high affinity and 
specificity to interact with the protein targets together with their low toxicity profiles. Many 
peptides that are currently administered do not meet the required criteria in cost, stability, 
long serum half-life and delivery. Nevertheless they serve as a source of inspiration for the 
development future generation peptide drugs. Evaluating the overall success, the increasing 
number of peptide leads going into clinical trials is a significant triumph for structural biology.  
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